Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorMedical
Phone949-250-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.72 billion
Profitability
Miscellaneous
Employees12,800
Next Earnings Date4/23/2019 (Estimated)
OptionableOptionable
Edwards Lifesciences (NYSE:EW) Frequently Asked Questions
What is Edwards Lifesciences' stock symbol?
Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."
When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?
Shares of Edwards Lifesciences split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.
How will Edwards Lifesciences' stock buyback program work?
Edwards Lifesciences announced that its Board of Directors has authorized a share repurchase program on Thursday, December 7th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its shares are undervalued.
How were Edwards Lifesciences' earnings last quarter?
Edwards Lifesciences Corp (NYSE:EW) announced its quarterly earnings results on Thursday, January, 31st. The medical research company reported $1.17 earnings per share for the quarter, hitting analysts' consensus estimates of $1.17. The medical research company had revenue of $977.70 million for the quarter, compared to analyst estimates of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same period last year, the firm posted $0.94 earnings per share. View Edwards Lifesciences' Earnings History.
When is Edwards Lifesciences' next earnings date?
What guidance has Edwards Lifesciences issued on next quarter's earnings?
Edwards Lifesciences updated its FY19 earnings guidance on Thursday, January, 31st. The company provided earnings per share guidance of $5.05-5.30 for the period, compared to the Thomson Reuters consensus estimate of $5.23. The company issued revenue guidance of $3.9-4.3 billion, compared to the consensus revenue estimate of $4.14 billion.Edwards Lifesciences also updated its Q1 guidance to $1.15-1.25 EPS.
What price target have analysts set for EW?
20 brokers have issued 12-month price objectives for Edwards Lifesciences' shares. Their forecasts range from $120.00 to $215.00. On average, they anticipate Edwards Lifesciences' share price to reach $174.70 in the next twelve months. This suggests that the stock has a possible downside of 10.8%. View Analyst Price Targets for Edwards Lifesciences.
What is the consensus analysts' recommendation for Edwards Lifesciences?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.
What are Wall Street analysts saying about Edwards Lifesciences stock?
Here are some recent quotes from research analysts about Edwards Lifesciences stock:
- 1. According to Zacks Investment Research, "Edwards Lifesciences exited the third quarter on a mixed note with earnings ahead of the Zacks Consensus Estimate and revenues lagging the same. Strong transcatheter valve sales in the domestic and overseas markets are a major positive. The company also registered strong sales within its Critical Care division banking on which it has raised Critical Care guidance. Further, management is upbeat about CMS opening a National Coverage Analysis to reconsider the National Coverage Determination released in 2012 for transcatheter aortic valve replacement. On the flip side, management expects underlying sales growth in THVT for 2018 to remain at around 12.5% because of limited contribution from Cardioband and a newly-revised rollout strategy for SAPIEN 3 Ultra. Also, tough competition in the cardiac devices market and reimbursement issues continue to raise concern. Overall, in the past three months, Edwards Lifesciences underperformed its industry." (10/25/2018)
- 2. Northland Securities analysts commented, "We analyze data on MitraClip + GDMT in HFpEF / HFrEF + FMR, & impact on existing clinical trials in both transcatheter mitral repair / replacement programs. There are a ton of unknowns, however, it is likely that: 1) Edwards PASCAL trial will need to be redesigned with MitraClip as the control (even though the trial is in DMR; Medtronic’ APOLLO trial, especially in HFrEF might" not need MitraClip as the comparator). 2) COAPT results are not applicable in real-world setting. Key Points We confess, we don’t have access to raw data in COAPT, hence it is impossible to make definitive arguments." (10/11/2018)
Has Edwards Lifesciences been receiving favorable news coverage?
Headlines about EW stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Edwards Lifesciences earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Edwards Lifesciences' key competitors?
Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Medtronic (MDT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Amgen (AMGN), Sanofi (SNY), AstraZeneca (AZN), Thermo Fisher Scientific (TMO), GlaxoSmithKline (GSK), CSL (CSL), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Anthem (ANTM).
What other stocks do shareholders of Edwards Lifesciences own?
Who are Edwards Lifesciences' key executives?
Edwards Lifesciences' management team includes the folowing people:
- Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
- Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
- Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
- Mr. Larry L. Wood, Corp. VP of Transcatheter Heart Valve (Age 53)
- Ms. Catherine M. Szyman, Corp. VP of Critical Care (Age 52)
Who are Edwards Lifesciences' major shareholders?
Edwards Lifesciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.86%), Oregon Public Employees Retirement Fund (5.09%), FMR LLC (3.65%), Bank of New York Mellon Corp (3.37%), Jennison Associates LLC (1.97%) and Brown Advisory Inc. (1.78%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.
Which institutional investors are selling Edwards Lifesciences stock?
EW stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, MERIAN GLOBAL INVESTORS UK Ltd, Orbimed Advisors LLC, Bank of New York Mellon Corp, Brown Advisory Inc., Scout Investments Inc., Bank of America Corp DE and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.
Which institutional investors are buying Edwards Lifesciences stock?
EW stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, Jennison Associates LLC, FMR LLC, BlackRock Inc., Legal & General Group Plc, Geode Capital Management LLC and Thrivent Financial for Lutherans. View Insider Buying and Selling for Edwards Lifesciences.
How do I buy shares of Edwards Lifesciences?
Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edwards Lifesciences' stock price today?
One share of EW stock can currently be purchased for approximately $195.9346.
How big of a company is Edwards Lifesciences?
Edwards Lifesciences has a market capitalization of $40.71 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.
What is Edwards Lifesciences' official website?
How can I contact Edwards Lifesciences?
Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]
MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
